Selected article for: "case fatality rate and disease case"

Author: Falzarano, Darryl; de Wit, Emmie; Martellaro, Cynthia; Callison, Julie; Munster, Vincent J.; Feldmann, Heinz
Title: Inhibition of novel ß coronavirus replication by a combination of interferon-a2b and ribavirin
  • Document date: 2013_4_18
  • ID: tgngoea8_3
    Snippet: The rapid identification of therapeutics is a high priority as there is currently no specific therapy or vaccine for nCoV and the resulting disease has been severe with a high case-fatality rate. The clinical experience from SARS suggests that a number of interventions including ribavirin with and without corticosteroids [12] [13] [14] , ribavirin with protease inhibitors 15, 16 and interferon (alfacon-1) with corticosteroids 17 may improve outco.....
    Document: The rapid identification of therapeutics is a high priority as there is currently no specific therapy or vaccine for nCoV and the resulting disease has been severe with a high case-fatality rate. The clinical experience from SARS suggests that a number of interventions including ribavirin with and without corticosteroids [12] [13] [14] , ribavirin with protease inhibitors 15, 16 and interferon (alfacon-1) with corticosteroids 17 may improve outcome, but a definitive treatment regimen was not clearly established 18 . Here we address the effectiveness in vitro of two antiviral drugs, interferon-a2b (IFN-a2b) and ribavirin, in an attempt to identify a therapeutic approach that can be immediately utilized in the clinic to benefit future cases.

    Search related documents:
    Co phrase search for related documents
    • antiviral drug and case fatality rate: 1, 2, 3, 4, 5, 6, 7, 8
    • antiviral drug and clinical experience: 1, 2, 3
    • antiviral drug and future case: 1, 2
    • antiviral drug and high case fatality rate: 1, 2
    • antiviral drug and high priority: 1, 2, 3, 4
    • antiviral drug and outcome improve: 1
    • antiviral drug and protease inhibitor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral drug and rapid identification: 1, 2, 3, 4, 5, 6, 7
    • antiviral drug and result disease: 1, 2, 3, 4
    • antiviral drug and specific therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • case fatality and clinical experience: 1, 2, 3, 4, 5
    • case fatality and future case: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • case fatality and high case fatality rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • case fatality and high priority: 1, 2, 3, 4, 5
    • case fatality and outcome improve: 1, 2, 3, 4, 5
    • case fatality and rapid identification: 1, 2, 3, 4
    • case fatality and result disease: 1, 2, 3, 4, 5, 6
    • case fatality and specific therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • case fatality rate and future case: 1, 2, 3, 4